Abstract:Periodontal disease (PD) is caused by microbial dysbiosis and accompanying adverse inflammatory responses. Due to its high incidence and association with various systemic diseases, disease-modifying treatments that modulate dysbiosis serve as promising therapeutic approaches. In this study, to simulate the pathophysiological situation, we established a "temporary ligature plus oral infection model" that incorporates a temporary silk ligature and oral infection with a cocktail of live Tannerella forsythia (Tf), Pophyromonas gingivalis (Pg), and Fusobacterium nucleatum (Fn) in mice and tested the efficacy of a new trivalent mucosal vaccine. It has been reported that Tf, a red complex pathogen, amplifies periodontitis severity by interacting with periodontopathic bacteria such as Pg and Fn. Here, we developed a recombinant mucosal vaccine targeting a surface-associated protein, BspA, of Tf by genetically combining truncated BspA with built-in adjuvant flagellin (FlaB). To simultaneously induce Tf-, Pg-, and Fn-specific immune responses, it was formulated as a trivalent mucosal vaccine containing Tf-FlaB-tBspA (BtB), Pg-Hgp44-FlaB (HB), and Fn-FlaB-tFomA (BtA). Intranasal immunization with the trivalent mucosal vaccine (BtB + HB + BtA) prevented alveolar bone loss and gingival proinflammatory cytokine production. Vaccinated mice exhibited significant induction of Tf-tBspA-, Pg-Hgp44-, and Fn-tFomA-specific IgG and IgA responses in the serum and saliva, respectively. The anti-sera and anti-saliva efficiently inhibited epithelial cell invasion by Tf and Pg and interfered with biofilm formation by Fn. The flagellin-adjuvanted trivalent mucosal vaccine offers a novel method for modulating dysbiotic bacteria associated with periodontitis. This approach leverages the adjuvant properties of flagellin to enhance the immune response, aiming to restore a balanced microbial environment and improve periodontal health.

Mucosal Vaccination Against Periodontal Disease: Current Status and Opportunities

Periodontal vaccines: Where we are now and where we can go

Advances and challenges in the development of periodontitis vaccines: A comprehensive review

Methods and Clinical Development of Adenovirus-Vectored Vaccines Against Mucosal Pathogens

Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuvants

Mucosal vaccines for viral diseases: Status and prospects

A Flagellin-Adjuvanted Trivalent Mucosal Vaccine Targeting Key Periodontopathic Bacteria

Mucoadhesive Vaccine Delivery Systems for the Oral Mucosa

Induction of Mucosal Immunity Through Systemic Immunization: Phantom or Reality?

Is the oral microbiome a source to enhance mucosal immunity against infectious diseases?

ORAL ROUTE AS METHOD FOR IMMUNIZING AGAINST MUCOSAL PATHOGENS

Vaccine Strategies to Elicit Mucosal Immunity

Development of mucosal vaccine delivery: an overview on the mucosal vaccines and their adjuvants

Cutting-edge research frontiers in oral cavity vaccines for respiratory diseases: a roadmap for scientific advancement

Current status of mucosal vaccines against SARS-CoV2: a hope for protective immunity

Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: Implication for treatment of periodontal infection and halitosis.

Advanced Oral Vaccine Delivery Strategies for Improving the Immunity

Immunogenic Characterization and Protection Against Streptococcus Mutans Infection Induced by Intranasal DNA Prime–protein Boost Immunization

The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines

Mucosal Vaccines for Moraxella Catarrhalis

SARS-CoV-2 Vaccines: The Advantage of Mucosal Vaccine Delivery and Local Immunity